Amphastar Pharmaceuticals, Inc. operates as a bio-pharmaceutical company.
The company is focusing on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, as w…
Analysis
Middle-of-the-road
Amphastar Pharmaceuticals, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.
On valuation, the picture is attractive. The owner-earnings multiple stands at 8.8×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around -5% a year, against analyst forecasts of 2%. The price, in other words, assumes less than the experts do.
Growth is tepid; the safety picture is adequate. The company scores 12/20 on our value-creation score: creating some value.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Jan 202390
67
2023202420252026
All-time high
96
Jan 2024
All-time low
56
Nov 2025
Average rank
76
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
96
49
28
56
Price/Earnings
36
83
37
57
Price/Book
67
46
13
44
Dividend Yield
1
1
1
1
Value (overall)
85
86
31
4
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.